Compare GITS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | XBIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | South Korea | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 6.9M |
| IPO Year | N/A | 2011 |
| Metric | GITS | XBIO |
|---|---|---|
| Price | $2.20 | $4.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 129.3K | 28.0K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $0.66 | $1.90 |
| 52 Week High | $7.09 | $13.93 |
| Indicator | GITS | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 66.89 |
| Support Level | $2.15 | $2.82 |
| Resistance Level | $2.29 | N/A |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 86.36 | 61.36 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.